![Tomas Navratil](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tomas Navratil
Corporate Officer/Principal chez
GLAUKOS CORPORATION
Fortune : 9 M $ au 31/05/2026
Profil
Tomas Navratil currently works at Glaukos Corp.
as Chief Development Officer since 2022 and is a Member of the Supervisory Board at Severomoravske Vodovody a Kanalizace Ostrava as.
Former positions include Director-Medical & Scientific Affairs at Inspire Pharmaceuticals, Inc., Executive Director-Clinical Research at Parion Sciences, Inc., General Manager at Nicox Ophthalmics, Inc., Executive VP, Global Head-Research & Development at Nicox SA, and Senior Vice President-Development at Envisia Therapeutics, Inc. Education includes undergraduate and doctorate degrees from The University of North Carolina at Charlotte.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GLAUKOS CORP 0,16 % | 10/04/2026 | 90 370 ( 0,16 % ) | 9 M $ | 31/05/2026 |
Postes actifs de Tomas Navratil
| Sociétés | Poste | Début |
|---|---|---|
| GLAUKOS CORPORATION | Corporate Officer/Principal | 01/04/2022 |
Severomoravske Vodovody a Kanalizace Ostrava as
 Severomoravske Vodovody a Kanalizace Ostrava as Water UtilitiesUtilities Engages in supply of drinking water and sewage services | Directeur/Membre du Conseil | - |
Anciens postes connus de Tomas Navratil
| Sociétés | Poste | Fin |
|---|---|---|
Nicox Ophthalmics, Inc.
 Nicox Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures ophthalmology pharmaceutical products | Corporate Officer/Principal | - |
Inspire Pharmaceuticals, Inc.
 Inspire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes ophthalmic products | Directeur Technique/Scientifique/R&D | - |
| NICOX SA | Directeur Technique/Scientifique/R&D | - |
Parion Sciences, Inc.
 Parion Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Develops new treatments for serious diseases in multiple therapeutic areas | Corporate Officer/Principal | - |
Envisia Therapeutics, Inc.
 Envisia Therapeutics, Inc. BiotechnologyHealth Technology Develops novel ocular therapies | Corporate Officer/Principal | - |
Formation de Tomas Navratil
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
19
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Inspire Pharmaceuticals, Inc.
Inspire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes ophthalmic products | Health Technology |
Parion Sciences, Inc.
Parion Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Develops new treatments for serious diseases in multiple therapeutic areas | Commercial Services |
Glaukos Corp.
 Glaukos Corp. Medical SpecialtiesHealth Technology Operates as an ophthalmic medical device company | Health Technology |
Nicox Ophthalmics, Inc.
Nicox Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures ophthalmology pharmaceutical products | Health Technology |
Nicox SA
 Nicox SA Pharmaceuticals: MajorHealth Technology Manufactures and sells ophthalmology biopharmaceuticals | Health Technology |
Severomoravske Vodovody a Kanalizace Ostrava as
Severomoravske Vodovody a Kanalizace Ostrava as Water UtilitiesUtilities Engages in supply of drinking water and sewage services | Utilities |
The University of North Carolina at Charlotte
 The University of North Carolina at Charlotte Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Envisia Therapeutics, Inc.
Envisia Therapeutics, Inc. BiotechnologyHealth Technology Develops novel ocular therapies | Health Technology |
